5/12/2020 4:03:23 PM
Curis Q1 Loss/share $0.28 Vs. Loss $0.30 Year Ago
3/19/2020 4:05:35 PM
Curis Q4 Loss/share $0.26 Vs. Loss $0.18 Year Ago
2/27/2020 8:03:12 AM
Curis Announces $30 Mln Common Stock Purchase Agreement With Aspire Capital Fund
1/13/2020 8:05:08 AM
Curis, DarwinHealth Collaborate To Characterize Biomarkers And Tumor Subtype Alignments For Fimepinostat In DLBCL
1/7/2020 8:06:40 AM
Curis Enters Option, License Agreement To Acquire Exclusive, Worldwide Rights From ImmuNext For Anti-VISTA Antibodies
12/6/2019 7:32:42 AM
Curis Announces Updated Preliminary Data From Phase 1 Dose Escalation Study Of CA-4948
12/6/2019 7:02:22 AM
Curis Announces Positive Safety, Tolerability And Pharmacokinetic Data In Phase 1 Study Of Fimepinostat With Venetoclax
11/5/2019 7:02:39 AM
Curis Q3 Net Loss Narrows To $6.4 Mln Or $0.19/shr From $7.2 Mln Or $0.22/shr Prior Year
9/12/2019 8:04:51 AM
Curis Says Promotes Bill Steinkrauss To CFO
8/6/2019 4:02:56 PM
Curis Q2 Loss Per Share $0.22 Vs Loss $0.26 Last Year
7/5/2019 4:06:42 PM
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)